Zika Virus Testing Market Size

Zika Virus Testing Market Analysis

The Zika Virus Testing Market size is estimated at USD 222.42 million in 2024, and is expected to reach USD 320.07 million by 2029, growing at a CAGR of 7.55% during the forecast period (2024-2029).

COVID-19 significantly impacted the zika virus testing market during the forecast period. The spread of infectious diseases increased with the rising prevalence of coronavirus; hence, the demand for testing to diagnose the zika virus also increased during the pandemic. An NCBI study published in October 2021 showed that Zika infection closely resembles COVID-19 and other arboviral infections and stated that there was a considerable risk of Zika Virus Disease spreading across the world, which is especially dangerous in the backdrop of the COVID-19 virus outbreak. Thus, public health measures, vector control, and early diagnosis, especially in the case of pregnant women, are suggested during the pandemic in India to control the spread of the disease. Hence, the similar nature of infection of both the COVID-19 and Zika virus led to an increasing zika virus testing for diagnosis purposes globally, thereby impacting the growth of the market during the pandemic period. Also, the rising focus on the Zika virus diagnosis during the post-pandemic period is expected to contribute to the market's growth over the forecast period.

Factors such as the increasing prevalence of zika virus infection and technological advancements in zika virus testing are the major factors driving the growth of the market studied. As per the WHO data in October 2022, Zika virus (ZIKV) infection has been known to be endemic in Africa and Southeast Asia. The consequent viral spread over the Pacific region led to an outbreak in the developed and emerging countries. In addition, there have been major outbreaks of Zika virus infection in Asia-Pacific (particularly India) and South American countries. Also, the WHO data updated in February 2022 stated that Zika transmission persists in several countries but is most common at low levels till 2021. Thus, the rising prevalence of Zika virus infection is one of the primary factors driving the market's growth over the forecast period.

The other prominent drivers of the market studied are increasing research and development by biopharmaceutical companies and technological advancements in diagnostic tests. On the Other hand, governments worldwide are focusing more on initiatives to halt zika virus transmission is driving the studied market growth. For instance, in May 2022, the government of Uttar Pradesh (India) launched the 'Zero Mission' 'Zero to eradicate vector-borne diseases such as Japanese encephalitis, dengue, malaria, typhoid, pneumonia, and Zika virus. Thus, the rising prevalence of Zika virus infection worldwide and government initiatives are among the primary factors driving the market's growth over the forecast period.

However, the excessive cost of testing kits is predicted to hinder market growth in the forecast period.